The predecessor to Intellipharmaceutics International was founded by Drs. Isa and Amina Odidi in 1998. The achievements of our founders include the development of numerous FDA approved and commercially successful controlled release drugs for others.

Since our founding, we have expanded our premises twice and have amassed an array of core assets, including seven proprietary drug delivery technologies, issued and pending patents, and a growing pipeline of ANDA and NDA product candidates.


We also have a successful history of establishing collaborative development and licensing arrangements with respected pharmaceutical companies. These arrangements are based on confidentiality and well-earned trust. The focus of these relationships is directed to getting the best drug product to market in the shortest possible time.

In October 2009, Intellipharmaceutics Ltd. entered into a corporate reorganization in which the successor company for its shareholders became Intellipharmaceutics International Inc. and became a publicly-traded company. Shares of our Company trade on the NASDAQ under the symbol "IPCI" and on the TSX under the symbol "IPCI".